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January 10, 2012:192–5immediate evaluation of procedure-related complications, and
post-interventional validation of treatment success with a total
procedure time of 61  13 min. Complementary to reduction of
radiation exposure and nephrotoxic contrast media, rtMRI guid-
ance, therefore, provides clinically relevant advantages over con-
ventional X-ray-fluoroscopy and warrants further attention. These
advantages should encourage future efforts to translate rtMRI-
guided TAVI into clinical application using commercial but
modified or entirely novel devices (2,3) and to overcome remaining
obstacles such as the development of suitable, MRI-compatible
Figure 1 Transsubclavian TAVI
After initial device position was confirmed in parasagittal and axial orientations
using cine-TrueFISP retro sequences (A), the stent valve was deployed step-
wise across the aortic annulus while monitoring with real-time TrueFISP imaging
(B). After implantation, cine-TrueFISP retro sequences were repeated to con-
firm valve positioning (C).guidewires.
(1). Among 1,030 Fidelis patients (Minneapolis, Minnesota) andPhilipp Kahlert, MD*
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Sprint Fidelis Leads
and Patient Mortality
We read with interest the report of all-cause mortality in patients
with Fidelis leads as compared with those with nonadvisory leads1,641 Quattro patients (Minneapolis, Minnesota) over a mean
follow-up period of 34.4 and 39.9 months, respectively, there was
no difference in adjusted survival rates. The authors contend that
their data support the current manufacturer’s strategy of “contin-
ued clinical follow-up with the addition of the Lead Integrity Alert
(LIA)” and conclude that this “argues against prophylactic removal
of a normally functioning Fidelis lead” (1). In the accompanying
editorial, Faddis (2) states that these data by Morrison et al. (1)
“provide valuable guidance” with respect to lead management
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January 10, 2012:192–5strategies for the advisory Fidelis lead. Despite their findings, the
authors recommend lead replacement in patients with Fidelis leads
who are pacemaker-dependent, of young age (50 years old),
physically active, and have preserved ejection fractions or secondary
prevention indications for defibrillator therapy (1).
In this referral population at 3 tertiary care centers managed
ith optimal surveillance and LIA, 45% of Fidelis failures were
ssociated with inappropriate shocks and 1 with presyncope and
entricular asystole requiring emergent temporary pacing. The
igh prevalence of inappropriate shocks despite optimal manage-
ent illustrates the potential harm associated with conservative
anagement given the association between shocks of any etiology
nd mortality (3) and the severe psychological disability frequently
een in these patients (4). As Faddis notes, this is the “price to be
aid” (2) for adherence to the recommended conservative strategy
f continued observation with LIA.
We agree that the decision to undertake any procedure man-
ates an assessment of risk versus risk. In contrast to the Canadian
eport (5), which did not specifically look at prophylactic extrac-
ion, our multicenter experience demonstrated the safety of Fidelis
ead extraction in experienced hands (557 leads, 100% complete
uccess, no deaths or major complications, and a minor complica-
ion rate of 0.34%) (6). Others have reported similar success with
idelis lead removal (7). Thus, in keeping with the Heart Rhythm
ociety Task Force on Lead Performance Policies and Guidelines,
hich state, “lead revision or replacement should be considered if
he risk of malfunction is likely to lead to patient death or serious
arm, and the risk of revision or replacement is believed to be less
han the risk of patient harm from the lead malfunction,” we
ontend that in patients undergoing generator replacement who do
ot have substantial life-limiting comorbidities, Fidelis lead re-
oval should be considered at experienced centers. Later removal
fter lead failure is likely to be more difficult and associated with a
igher risk of complications, in addition to the potential conse-
uences of lead failure.
In summary, it is our opinion that the results of the current
tudy should not be interpreted to mean that continued observa-
ion of the Fidelis lead should be the universal management
trategy. We assert that decisions regarding extraction of the
idelis lead must be made on a case-by-case basis considering
ultiple patient- and physician-related variables because a conser-
ative approach can be associated with significant harm and lead
xtraction has the potential for significant morbidity and mortality.
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The ATRIA Risk Scheme to Predict
Warfarin-Associated Hemorrhage
Not Ready for Clinical Use
Fang et al. (1) describe their bleeding risk scheme for anticoagu-
lated patients with atrial fibrillation (AF), which includes 5
weighted risk factors: anemia, severe renal disease, age 75 years and
older, previous hemorrhage, and diagnosed hypertension (1).
We welcome efforts to assess bleeding risk in AF patients
requiring anticoagulation, but a number of major concerns regard-
ing the derivation of this new schema may limit its clinical
applicability. First, the ATRIA cohort consisted exclusively of
anticoagulated AF patients (1), and rates of warfarin-associated
hemorrhage may be underestimated due to the selected “warfarin-
experienced” cohort and may not be applicable to patients initiat-
ing anticoagulation. Second, their previous study (2) reported that
risk factors included in their new schema (previous intracranial/
gastrointestinal/other hemorrhage, renal insufficiency) were con-
traindications to warfarin (2). Patients with1 of these risk factors
were significantly less likely to receive warfarin (2) and conse-
quently were excluded from current analyses (1). Third, several
well-established major risk factors for bleeding, namely, recent
(90 days) hemorrhage (hazard ratio: 0.3; 95% confidence inter-
val: 0.1 to 0.7), antiplatelet treatment (clopidogrel/ticlopidine),
and reduced platelet count (3), had point estimates that appeared
protective of future bleeding in their analyses (1).
Fourth, intensity of the anticoagulation effect (i.e., quality of
INR control) plus treatment with aspirin and nonsteroidal anti-
inflammatory drugs, which are important bleeding risk factors (3),
were not included in the study (1). Fifth, no rationale was provided
for only including risk factors with hazard ratios1.5 in the initial
model, resulting in previous stroke, a well-established risk factor
for bleeding (3), being excluded.
Sixth, Fang et al. (1) included age 75 years and older in their
bleeding prediction scheme, despite bleeding risk increasing from
age 65 and older (3,4), and greater risk associated with age 65 and
older found in initial analyses (1). Also noteworthy is the inclusion
of diagnosed hypertension (1), despite evidence demonstrating
that well-controlled hypertension is not significantly associated
with bleeding in AF patients (3).
